4640 Results

People

  1. Saltz
    Saltz
  2. O'Reilly
    O'Reilly
  3. Abou-Alfa
    Abou-Alfa
  4. Kelsen
    Kelsen
  5. Ilson
    Ilson
  6. Kemeny
    Kemeny
  7. Janjigian
    Janjigian
  8. Reidy
    Reidy
  9. Jarnagin
    Jarnagin
  10. D'Angelica
    D'Angelica

Groups

  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)
  7. Epidemiology and Biostatistics (828)
  8. GSK Faculty (793)
  9. Department of Pathology and Laboratory Medicine (723)
  10. Biostatistics Service (661)
  1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)
    Meeting Abstract

    Abou-Alfa, G. K.; Niedzwieski, D.; Knox, J. J.; Kaubisch, A.; Posey, J.; Tan, B. R.; Kavan, P.; Goel, R.; Lammers, P. E.; Bekaii-Saab, T. S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC)
    Meeting Abstract

    Abou-Alfa, G. K.; Sangro, B.; Morse, M.; Zhu, A. X.; Kim, R. D.; Cheng, A. L.; Kudo, M.; Kang, Y. K.; Chan, S. L.; Antal, J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Assessing the potential for enhanced antibody-dependent cellmediated cytotoxicity (ADCC) by combining the CD137 antibody urelumab with rituximab or cetuximab in patients with refractory lymphoma or select advanced solid tumors
    Meeting Abstract

    Segal, N. H.; Sharma, M.; Le, D. T.; Ott, P. A.; Ferris, R. L.; Zelenetz, A. D.; Neelapu, S. S.; Levy, R.; Lossos, I. S.; Jacobson, C.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Local intratumoral treatment with low-dose CD40 and TLR4 agonists overcomes resistance to PD-1 blockade to control tumors systemically
    Meeting Abstract

    Khalil, D. N.; Campesato, L. F.; Li, Y.; Merghoub, T.; Wolchok, J. D.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies
    Meeting Abstract

    Massarelli, E.; Segal, N. H.; Ribrag, V.; Melero, I.; Gangadhar, T. C.; Urba, W.; Schadendorf, D.; Ferris, R. L.; Houot, R.; Morschhauser, F.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Preliminary efficacy from a phase I/II study of the natural killer cell–targeted antibody lirilumab in combination with nivolumab in squamous cell carcinoma of the head and neck
    Meeting Abstract

    Leidner, R.; Kang, H.; Haddad, R.; Segal, N. H.; Wirth, L. J.; Ferris, R. L.; Hodi, F. S.; Sanborn, R. E.; Gajewski, T. F.; Sharfman, W.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Rituximab for prevention of recurrent pregnancy related thrombotic thrombocytopenic purpura in high risk patients with previous episodes of thrombotic thrombocytopenic purpura during pregnancy
    Meeting Abstract

    Mariampillai, A. I.; Garrison, M.; Zervoudakis, A. A.
    Blood (2016)

    Fulltext@MSK | Save
  • Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database
    Journal Article

    Papamichael, D.; Renfro, L. A.; Matthaiou, C.; Yothers, G.; Saltz, L.; Guthrie, K. A.; Van Cutsem, E.; Schmoll, H. J.; Labianca, R.; André, T.; more...
    Journal of Geriatric Oncology (2016)

    Fulltext@MSK | Save
  • Treatment of older women with endometrial cancer: Improving outcomes with personalized care
    Journal Article

    Duska, L.; Shahrokni, A.; Powell, M.
    American Society of Clinical Oncology Educational Book (2016)

    Fulltext@MSK | Save
  • Prospective phase II trial of combination hepatic artery and systemic chemotherapy for unresectable colorectal liver metastases: Long-term results and curative potential
    Meeting Abstract

    Ma, L. W.; Kemeny, N. E.; Capanu, M.; Chou, J.; Cercek, A.; Kingham, T. P.; Allen, P. J.; DeMatteo, R. P.; Jarnagin, W. R.; D'Angelica, M. I.
    Journal of the American College of Surgeons (2016)

    Fulltext@MSK | Save